Therapy Areas: Oncology
Innate Pharma receives HSR clearance for expansion of collaboration with Sanofi on NK Cell Engagers
25 January 2023 -

Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA), an oncology-focused biotech company, on Wednesday reported the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with healthcare company Sanofi.

This licensing agreement is now effective, under which Sanofi is licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate's ANKET (Antibody-based NK Cell Engager Therapeutics) platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.

Also, Sanofi has the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialisation.

Under the terms of the agreement, Innate said it will receive EUR25m upfront payment and up to EUR1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.



Related Headlines